4th Mar 2025 11:16
Hikma Pharmaceuticals PLC - EIP Vesting
LONDON, 4 March 2025: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) ("Hikma") (LEI: 549300BNS685UXH4JI75) announces that the following Persons Discharging Managerial Responsibility ("PDMR") have received shares as a result of the vesting or exercise of their conditional share awards which were granted on 25 February 2022 under the 2014 Executive Incentive Plan ("EIP") Element C and on 17 March 2016 under the EIP Element B.
Notification and public disclosure of transactions by persons discharging managerial responsibilities
Said Darwazah
1 | Details of the person discharging managerial responsibilities / person closely associated | ||
a) | Name | Said Darwazah | |
2 | Reason for the notification | ||
a) | Position/status | Executive Chairman | |
b) | Initial notification /Amendment | Initial notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Hikma Pharmaceuticals PLC | |
b) | LEI | 549300BNS685UXH4JI75 | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards under the EIP Element C. All Shares were retained. | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
Nil | 18,420 | ||
d) | Aggregated information
| Price(s): nil Volume(s): 18,420 | |
e) | Date of the transaction | 28 February 2025 | |
f) | Place of the transaction | London Stock Exchange (XLON) | |
Riad Mishlawi
1 | Details of the person discharging managerial responsibilities / person closely associated | ||
a) | Name | Riad Mishlawi | |
2 | Reason for the notification | ||
a) | Position/status | Chief Executive Officer | |
b) | Initial notification /Amendment | Initial notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Hikma Pharmaceuticals PLC | |
b) | LEI | 549300BNS685UXH4JI75 | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards under the EIP Element C and exercise of conditional awards under the EIP Element B. All Shares were retained. | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
Nil | EIP Award, Element C: 18,691 | ||
Nil | EIP Award, Element B: 19,890 | ||
d) | Aggregated information
| Price(s): nil Volume(s): 38,581 | |
e) | Date of the transaction | 28 February 2025 | |
f) | Place of the transaction | London Stock Exchange (XLON) | |
Mazen Darwazah
1 | Details of the person discharging managerial responsibilities / person closely associated | ||
a) | Name | Mazen Darwazah | |
2 | Reason for the notification | ||
a) | Position/status | Executive Vice Chairman | |
b) | Initial notification /Amendment | Initial notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Hikma Pharmaceuticals PLC | |
b) | LEI | 549300BNS685UXH4JI75 | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards under the EIP Element C. All Shares were retained. | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
Nil | 14,844 | ||
d) | Aggregated information
| Price(s): nil Volume(s): 14,844 | |
e) | Date of the transaction | 28 February 2025 | |
f) | Place of the transaction | London Stock Exchange (XLON) | |
Khalid Nabilsi
1 | Details of the person discharging managerial responsibilities / person closely associated | ||
a) | Name | Khalid Nabilsi | |
2 | Reason for the notification | ||
a) | Position/status | PDMR | |
b) | Initial notification /Amendment | Initial notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Hikma Pharmaceuticals PLC | |
b) | LEI | 549300BNS685UXH4JI75 | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards under the EIP Element C. All Shares were retained. | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
Nil | 17,003 | ||
d) | Aggregated information | Price(s): nil Volume(s): 17,003 | |
e) | Date of the transaction | 28 February 2025 | |
f) | Place of the transaction | London Stock Exchange (XLON) | |
Bassam Kanaan
1 | Details of the person discharging managerial responsibilities / person closely associated | ||
a) | Name | Bassam Kanaan | |
2 | Reason for the notification | ||
a) | Position/status | PDMR | |
b) | Initial notification /Amendment | Initial notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Hikma Pharmaceuticals PLC | |
b) | LEI | 549300BNS685UXH4JI75 | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards under the EIP Element C. All Shares were retained. | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
Nil | 16,472 | ||
d) | Aggregated information | Price(s): nil Volume(s): 16,472 | |
e) | Date of the transaction | 28 February 2025 | |
f) | Place of the transaction | London Stock Exchange (XLON) | |
Susan Ringdal
1 | Details of the person discharging managerial responsibilities / person closely associated | ||
a) | Name | Susan Ringdal | |
2 | Reason for the notification | ||
a) | Position/status | PDMR | |
b) | Initial notification /Amendment | Initial notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Hikma Pharmaceuticals PLC | |
b) | LEI | 549300BNS685UXH4JI75 | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards under the EIP Element C. | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
Nil | 8,851 | ||
d) | Aggregated information | Price(s): nil Volume(s): 8,851 | |
e) | Date of the transaction | 28 February 2025 | |
f) | Place of the transaction | London Stock Exchange (XLON) | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | |
b) | Nature of the transaction | Shares sold to cover tax following the vesting of conditional awards under the EIP Element C. | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
£21.71 | 4,173 | ||
d) | Aggregated information | Price(s): £21.71 Volume(s): 4,173 Total(s): £90,596.87 | |
e) | Date of the transaction | 28 February 2025 | |
f) | Place of the transaction | London Stock Exchange (XLON) | |
Hussein Arkhagha
1 | Details of the person discharging managerial responsibilities / person closely associated | ||
a) | Name | Hussein Arkhagha | |
2 | Reason for the notification | ||
a) | Position/status | PDMR | |
b) | Initial notification /Amendment | Initial notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Hikma Pharmaceuticals PLC | |
b) | LEI | 549300BNS685UXH4JI75 | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards under the EIP Element C. All Shares were retained. | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
Nil | 8,675 | ||
d) | Aggregated information | Price(s): nil Volume(s): 8,675 | |
e) | Date of the transaction | 28 February 2025 | |
f) | Place of the transaction | London Stock Exchange (XLON) | |
Helen MiddlemistGroup Company Secretary
+44 (0)20 7399 2760
4 March 2025
Related Shares:
Hikma Pharmaceuticals